The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients
Open accessAbstract
BACKGROUND: There is no established therapy for hepatitis E virus (HEV) infection. The aim of this retrospective, multicenter case series was to assess the effects of ribavirin as monotherapy for solid-organ transplant recipients with prolonged HEV viremia. METHODS: We examined the records of 59 patients who had received a solid-organ transplant (37 kidney-transplant recipients, 10 liver-transplant recipients, 5 heart-transplant recipients, 5 kidney and pancreas-transplant recipients, and 2 lung-transplant recipients). Ribavirin therapy was initiated a median of 9 months (range, 1 to 82) after the diagnosis of HEV infection at a median dose of 600 mg per day (range, 29 to 1200), which was equivalent to 8.1 mg per kilogram of body weight per day (range, 0.6 to 16.3). Patients received ribavirin for a median of 3 months (range, 1 to 18); 66% of the patients received ribavirin for 3 months or less. RESULTS: All the patients had HEV viremia when ribavirin was initiated (all 54 in whom genotyping was performed had HEV genotype 3). At the end of therapy, HEV clearance was observed in 95% of the patients. A recurrence of HEV replication occurred in 10 patients after ribavirin was stopped. A sustained virologic response, defined as an undetectable serum HEV RNA level at least 6 months after cessation of ribavirin therapy, occurred in 46 of the 59 patients (78%). A sustained virologic response was also observed in 4 patients who had a recurrence and were re-treated for a longer period. A higher lymphocyte count when ribavirin therapy was initiated was associated with a greater likelihood of a sustained virologic response. Anemia was the main identified side effect and required a reduction in ribavirin dose in 29% of the patients, the use of erythropoietin in 54%, and blood transfusions in 12%. CONCLUSIONS: This retrospective, multicenter study showed that ribavirin as monotherapy may be effective in the treatment of chronic HEV infection; a 3-month course seemed to be an appropriate duration of therapy for most patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients
Kamar, N., Selves, J., Mansuy, J.-M., Ouezzani, L., Péron, J.-M., Guitard, J., Cointault, O., Esposito, L., Abravanel, F., Danjoux, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706992 · Cited by 1,350
Self-citationLAMIVUDINE AS INITIAL TREATMENT FOR CHRONIC HEPATITIS B IN THE UNITED STATES
Ules, J., Ienstag, L. D., Chiff, E. U. R. S., Right, L. W., Errillo, R. O. P. P., Ann, L. H., Rowther, L. Y. C., Ondreay, D. C., Oessner, M. A. W., Ubin, M. A. R., et al. (1999) · Cited by 1,116
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Kamar, N., Bendall, R. P., Abravanel, F., Xia, N., Ijaz, S., Izopet, J., & Dalton, H. R. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61849-7 · Cited by 925
Self-citationEvidence for a Virus in Non-A, Non-B Hepatitis Transmitted via the Fecal-Oral Route
Balayart, M. S., Andjaparidze, A. G., Savinskaya, S. S., Ketiladze, E. S., Braginsky, D. M., Savinov, A. P., & Poleschuk, V. F. (1983) · Intervirology · doi:10.1159/000149370 · Cited by 897
Persistent Carriage of Hepatitis E Virus in Patients with HIV Infection
Dalton, H. R., Bendall, R. P., Keane, F. E., Tedder, R. S., & Ijaz, S. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0903778 · Cited by 547
Hoofnagle, J. H., Nelson, K. E., & Purcell, R. H. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1204512 · Cited by 479
O'Brien, S., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., Blum, K. A., Grant, B., Richards, D. A., Coleman, M., Wierda, W. G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70513-8 · Cited by 466
Cited by
EASL Clinical Practice Guidelines on hepatitis E virus infection
Dalton, H. R., Kamar, N., Baylis, S. A., Moradpour, D., Wedemeyer, H., & Negro, F. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.005 · Cited by 665
Self-citationThe honolulu liver disease cluster at the medical center: Its mysteries and challenges
Teschke, R., & Eickhoff, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040476 · Cited by 29
Teschke, R., Schwarzenboeck, A., Frenzel, C., Schulze, J., Eickhoff, A., & Wolff, A. (2016) · Annals of Hepatology · doi:10.5604/16652681.1184237 · Cited by 29
LeDesma, R., Heller, B., Biswas, A., Maya, S., Gili, S., Higgins, J., & Ploss, A. (2023) · eLife · doi:10.7554/elife.80529 · Cited by 22
Metadata
- Authors
- Kamar, N., Izopet, J., Tripon, S., Bismuth, M., Hillaire, S., Dumortier, J., Radenne, S., Coilly, A., Garrigue, V., D'Alteroche, L., Buchler, M., Couzi, L., Lebray, P., Dharancy, S., Minello, A., Hourmant, M., Roque-Afonso, A.-M., Abravanel, F., Pol, S., Rostaing, L., & Mallet, V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-03-20
- Volume
- 370
- Issue
- 12
- Pages
- 1111-1120
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058230403
- Cited by
- 520
- References
- 21
- FWCI
- 32.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients. https://app.cochat.ai/papers/10.1056/nejmoa1215246
- The paper
- Kamar, N., Izopet, J., Tripon, S., Bismuth, M., Hillaire, S., Dumortier, J., Radenne, S., Coilly, A., Garrigue, V., D'Alteroche, L., Buchler, M., Couzi, L., Lebray, P., Dharancy, S., Minello, A., Hourmant, M., Roque-Afonso, A.-M., Abravanel, F., Pol, S., . . . Mallet, V. (2014). Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1215246
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.